AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

FDA OKs Novartis’ Exelon Patch for Severe Alzheimer’s

 Uncategorized  Comments Off on FDA OKs Novartis’ Exelon Patch for Severe Alzheimer’s
Jun 292013
 

Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer’s disease

http://www.pharmalive.com/fda-oks-novartis-exelon-patch-for-alzheimers

Exelon Patch (rivastigmine transdermal system) contains rivastigmine, a reversible cholinesterase inhibitor known chemically as (S)- 3-[1-(dimethylamino) ethyl]phenyl ethylmethylcarbamate. It has an empirical formula of C14H22N2O2 as the base and a molecular weight of 250.34 (as the base). Rivastigmine is a viscous, clear, and colorless to yellow to very slightly brown liquid that is sparingly soluble in water and very soluble in ethanol, acetonitrile, n-octanol and ethyl acetate.

The distribution coefficient at 37°C in n-octanol/phosphate buffer solution pH 7 is 4.27.

 

 

EXELON PATCH (rivastigmine) Structural Formula Illustration

Exelon Patch is for transdermal administration. The patch is a four-layer laminate containing the backing layer, drug matrix, adhesive matrix and overlapping release liner (see Figure 1). The release liner is removed and discarded prior to use.

Figure 1: Cross Section of the Exelon Patch

 

EXELON PATCH (rivastigm ine transdermal system) Figure 1 Illustration

Layer 1: Backing Film
Layer 2: Drug Product (Acrylic) Matrix
Layer 3: Adhesive (Silicone) Matrix
Layer 4: Release Liner (removed at time of use)

Excipients within the formulation include acrylic copolymer, poly(butylmethacrylate, methylmethacrylate), silicone adhesive applied to a flexible polymer backing film, silicone oil, and vitamin E.

 

 

 

 

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: